Niagen Bioscience Inc (NAGE) Stock Score, Valuation & Financial Research
Niagen Bioscience Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 67/100.
Quick answer for NAGE
Niagen Bioscience Inc currently has a Wall Street Score of 67/100. The stored market price is $3.04. Its financial score is 45/100. Its valuation score is 97/100. These figures are a research snapshot, not a buy or sell recommendation.
What Niagen Bioscience Inc does
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon,
NAGE financial snapshot
- Wall Street Score:
- 67/100
- Current price:
- $3.04
- Market capitalization:
- $242.1M
- Revenue:
- $130.4M
- Net income:
- $18.6M
- Free cash flow:
- $13.1M
- Cash:
- $66.5M
- Total debt:
- $2.6M
- EPS:
- 0.22
- P/E ratio:
- 13.8x
- Financial score:
- 45/100
- Valuation score:
- 97/100
- Revenue score:
- 39/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $13.1M, showing positive cash generation.
- The balance sheet shows $66.5M of cash versus $2.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 45/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NAGE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.